Apoptosis signal-regulating kinase inhibitors

Abstract

The present invention relates to compounds of Formula (I): Wherein variables are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, COPD, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases.

What is claimed is: 
     
         1 - 13 . (canceled) 
     
     
         14 . A compound of Formula (I): 
       
         
           
           
               
               
           
         
         wherein: 
         R 1  is C 1 -C 3  alkyl or C 3 -C 6  cycloalkyl, wherein the alkyl or cycloalkyl is optionally substituted with one to three halogen atoms; 
         R 2  is hydrogen or C 1 -C 6  alkyl wherein the alkyl is optionally substituted with halo; 
         R 3  is hydrogen or C 1 -C 3  alkyl; 
         R 4  is hydrogen or C 1 -C 3  alkyl; 
         R 5  is hydrogen, C 1 -C 3  alkyl, OR a  or —NHR a ; 
         R 6  is hydrogen, C 1 -C 3  alkyl, C 1 -C 3  haloalkyl, or C 3 -C 6  cycloalkyl wherein the cycloalkyl is optionally substituted with C 1 -C 3  alkyl, C 1 -C 3  haloalkyl, or 1 or 2 halogen atoms;
 R a  and R b  are independently hydrogen, C 1 -C 3  alkyl or R a  and R b  combine with the nitrogen atom to which they are attached to form a four to six member heterocyclic ring optionally containing a heteroatom chosen from oxygen and nitrogen, wherein the heterocyclic ring is optionally substituted by one or two substituents independently chosen from alkyl of 1-4 carbon atoms and hydroxyl; 
 
         or a pharmaceutically acceptable salt or enantiomer thereof. 
       
     
     
         15 . The compound of  claim 14 , wherein:
 R 1  is cyclopropyl or 1,1,1-trifluoropropan-2-yl;   R 2 , R 3 , R 4  and R 5  are all hydrogen; and   R 6  is cyclopropyl.   
     
     
         16 . The compound of  claim 15 , wherein R 1  and R 6  are both cyclopropyl. 
     
     
         17 . The compound of  claim 16 , chosen from:
 4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)thiazol-4-yl)-5-morpholinopicolinamide;   4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)thiazol-4-yl)-5-(3-hydroxy-3-methylazetidin-1-yl)picolinamide;   5-(azetidin-1-yl)-4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide;   4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)thiazol-4-yl)-5-(pyrrolidin-1-yl)picolinamide;   4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)thiazol-4-yl)-5-(piperidin-1-yl)picolinamide;   4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)thiazol-4-yl)-5-(4-hydroxy-4-methylpiperidin-1-yl)picolinamide;   4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)thiazol-4-yl)-5-(4-methylpiperazin-1-yl)picolinamide; and   4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)thiazol-4-yl)-5-morpholinopicolinamide.   
     
     
         18 . The compound of  claim 14 , wherein:
 R 1  is 1,1,1-trifluoropropan-2-yl;   R 2 , R 3 , R 4  and R 5  are all hydrogen; and   R 6  is cyclopropyl.   
     
     
         19 . The compound of  claim 18 , chosen from:
 (S)-4-(4-cyclopropyl-1H-imidazol-1-yl)-5-morpholino-N-(2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide;   (S)-4-(4-cyclopropyl-1H-imidazol-1-yl)-5-(3-hydroxy-3-methylazetidin-1-yl)-N-(2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide;   (S)-4-(4-cyclopropyl-1H-imidazol-1-yl)-5-(dimethylamino)-N-(2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide;   (S)-5-(azetidin-1-yl)-4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide;   (S)-4-(4-cyclopropyl-1H-imidazol-1-yl)-5-(pyrrolidin-1-yl)-N-(2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide;   4-(4-cyclopropyl-1H-imidazol-1-yl)-5-(3-hydroxypyrrolidin-1-yl)-N-(2-(4-((S)-1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide;   (S)-4-(4-cyclopropyl-1H-imidazol-1-yl)-5-(piperidin-1-yl)-N-(2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide;   (S)-4-(4-cyclopropyl-1H-imidazol-1-yl)-5-(4-hydroxy-4-methylpiperidin-1-yl)-N-(2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide; and   (S)-4-(4-cyclopropyl-1H-imidazol-1-yl)-5-(4-methylpiperazin-1-yl)-N-(2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide.   
     
     
         20 . A pharmaceutical composition comprising a compound according to  claim 17  and at least one pharmaceutically acceptable excipient. 
     
     
         21 . A pharmaceutical composition comprising a compound according to  claim 19  and at least one pharmaceutically acceptable excipient. 
     
     
         22 . A method of treating ASK1-mediated conditions in a human patient comprising administering a therapeutic amount of a compound according to  claim 17 . 
     
     
         23 . A method of treating ASK1-mediated conditions in a human patient comprising administering a therapeutic amount of a compound according to  claim 19 .